Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism

Molecular Cancer Therapeutics

Volumn 6, Issue 10, 2007, Pages 2777-2785

  Roberts, Caroline G ^a   Gurisik, Ebru ^a   Biden, Trevor J ^a   Sutherland, Robert L ^a,b   Butt, Alison J ^a,b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; BIM PROTEIN; CERAMIDE; ESTROGEN RECEPTOR; LINOLEIC ACID; PERSIN; PLANT TOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; COMBINATION CHEMOTHERAPY; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIPID METABOLISM; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR GENE; TRANSCRIPTION REGULATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CERAMIDES; DRUG SYNERGISM; ESTROGEN ANTAGONISTS; FATTY ALCOHOLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; LIGANDS; LIPIDS; MEMBRANE PROTEINS; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 35948972876     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0374     Document Type: Article

References (34)

1. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-13.
2. Simonds HM, Miles D. Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor. Expert Opin Biol Ther 2007;7:487-91.
3. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005;12:S47-59.
4. Nishino H, Murakoshi M, Mou XY, et al. Cancer prevention by phytochemicals. Oncology 2005;69:38-40.
5. Butt AJ, Roberts CG, Seawright AA, et al. A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 2006;5:2300-9.
6. Oelrichs PB, Ng JC, Seawright AA, Ward A, Schaffeler L, MacLeod JK. Isolation and identification of a compound from avocado (Persea americana) leaves which causes necrosis of the acinar epitheliumof the lactating mammary gland and the myocardium. Nat Toxins 1995;3:344-9.
7. Strasser A, Puthalakath H, Bouillet P, et al. The role of Bim, a proapoptotic BH3-only member of the Bcl-2 family, in cell-death control. Ann N Y Acad Sci 2000;917:541-8.
8. Tan T-T, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227-38.
9. Ip C, Dong Y, Ip MM, et al. Conjugated linoleic acid isomers and mammary cancer prevention. Nutr Cancer 2002;43:52-8.
10. Ip C, Singh M, Thompson HJ, Scimeca JA. Conjugated linoleic acid suppresses mammary carcinogenesis and proliferative activity of the mammary gland in the rat. Cancer Res 1994;54:1212-5.
11. Menendez JA, Colomer R, Lupu R. ω-6 polyunsaturated fatty acid γ-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: γ-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. Int J Cancer 2004;109:949-54.
12. Durgam VR, Fernandes G. The growth inhibitory effect of conjugated linoleic acid on MCF-7 cells is related to estrogen response system. Cancer Lett 1997;116:121-30.
13. Kenny FS, Gee JM, Nicholson RI, et al. Effect of dietary GLA+/- tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts. Int J Cancer 2001;92:342-7.
14. Tanmahasamut P, Liu J, Hendry LB, Sidell N. Conjugated linoleic acid blocks estrogen signaling in human breast cancer cells. J Nutr 2003;134:674-80.
15. Kenny FS, Pinder SE, Ellis IO, et al. γ Linolenic acid with tamoxifen as primary therapy in breast cancer. Int J Cancer 2000;85:643-8.
16. Butt AJ, Dickson KA, Jambazov S, Baxter RC. Enhancement of tumor necrosis factor-α-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology 2005;146:3113-22.
17. Motta S, Monti M, Sesana S, Caputo R, Carelli S, Ghidoni R. Ceramide composition of the psoriatic scale. Biochem Biophys Acta 1993;1182:147-51.
18. Menendez JA, Ropero S, Lupu R, Colomer R. ω-6 polyunsaturated fatty acid γ-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: relationship to lipid peroxidation and HER-2/neu expression. Oncol Rep 2004;11:1241-52.
19. Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Res Treat 2004;84:151-60.
20. Cabot MC, Giuliano AE, Volner A, Han TY. Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett 1996;394:129-31.
21. Lavie Y, Cao H-t, Volner A, et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem1997;272:16 82-7.
22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
23. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005;591:247-63.
24. Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res 2006;12:1001-7s.
25. Buchanan MR. Linoleic acid metabolites in health and disease. Adv Exp Med Biol 1999;469:463-9.
26. Robertson JFR. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 2004;30:695-706.
27. Woodcock J. Sphingosine and ceramide signalling in apoptosis. IUBMB Life 2006;58:462-6.
28. Siskind LJ. Mitochondrial ceramide and the induction of apoptosis. J Bioenerg Biomembr 2005;37:143-53.
29. Modrak DE, Gold DV, Goldenberg DM. Sphingolipid targets in cancer therapy. Mol Cancer Ther 2006;5:200-8.
30. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE, Cabot MC. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 2001;47:444-50.
31. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 1998;18:475-80.
32. Lucci A, Han T-Y, Liu Y-Y, Giuliano AE, Cabot MC. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol 1999;15:541-6.
33. Basu S, Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene 1998;17:3277-85.
34. 2-terminal kinase. Cancer Res 2004;64:7852-6.